Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma plc (RPRX), sold 116,800 shares at $59.97 ($6.0M) on 2026-08-18, disclosed to the SEC on 2026-08-19.
Scheduled sale ($6.0M) by EVP & Chairman, Partnering under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $59.97 | 100,000 | $6.0M | 100.0% |
| 2 | $0.00 | 16,800 | $0 | 0.0% |
| Total | $51.35 avg | 116,800 | $6.0M | 100% |
| Filing → |
| RPRX | SELL | 2026-06-25 | $8.2M | — | Filing → |
| RPRX | BUY | 2020-06-23 | $2.0M | — | Filing → |